AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
10.97
+0.61 (5.89%)
At close: Aug 13, 2026, 4:00 PM EDT
10.96
-0.01 (-0.09%)
After-hours: Aug 13, 2026, 7:59 PM EDT
AbCellera Biologics Revenue
AbCellera Biologics had revenue of $4.05M in the quarter ending June 30, 2026, a decrease of -76.29%. This brings the company's revenue in the last twelve months to $66.17M, up 101.28% year-over-year. In the year 2025, AbCellera Biologics had annual revenue of $75.13M with 160.56% growth.
Revenue (ttm)
$66.17M
Revenue Growth
+101.28%
P/S Ratio
50.83
Revenue / Employee
$117,740
Employees
562
Market Cap
3.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75.13M | 46.30M | 160.56% |
| Dec 31, 2024 | 28.83M | -9.19M | -24.17% |
| Dec 31, 2023 | 38.03M | -447.40M | -92.17% |
| Dec 31, 2022 | 485.42M | 110.22M | 29.38% |
| Dec 31, 2021 | 375.20M | 142.05M | 60.92% |
| Dec 31, 2020 | 233.16M | 221.54M | 1,907.88% |
| Dec 31, 2019 | 11.61M | 2.78M | 31.49% |
| Dec 31, 2018 | 8.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 606.33M |
| Arcutis Biotherapeutics | 463.98M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| uniQure | 18.67M |
| Alumis | 8.40M |
| NewAmsterdam Pharma Company | 7.12M |
| Immunome | 4.02M |
ABCL News
- 1 day ago - AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants - Business Wire
- 2 days ago - AbCellera announces $200M common stock, warrants offering - TheFly
- 2 days ago - AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - Business Wire
- 2 days ago - AbCellera price target raised to $30 from $12 at Truist - TheFly
- 3 days ago - AbCellera price target raised to $25 from $13 at JonesResearch - TheFly
- 3 days ago - AbCellera Biologics Slides: Corporate presentation - Filings
- 3 days ago - AbCellera Biologics Transcript: Study result - Transcripts
- 3 days ago - AbCellera Biologics Press release: Study result - Filings